Patología Molecular del Cáncer
Buscador de publicaciones
Sólo se han incluido artículos originales, editoriales y revisiones.
-
Borque-Fernando Á, Alonso-Gordoa T, Juan-Fita MJ, Lopez Campos F, Pérez-Fentes DA, Vilaseca A, Moretones Agut C, Usán P, Maroto Rey P.
Multidisciplinary expert consensus on treatment intensification in metastatic androgen pathway modulation-sensitive prostate cancer: a case-based RAND/UCLA analysis.
Drugs in Context . 15: .
-
Ariño-Palao C, Carretero-Barrio I, Martos-Meléndez S, Caniego-Casas T, Rosas M, Martínez-Jañez N, Fernández-Abad M, Sánchez MC, Presa-Abos T, Zamora J, Martínez-Aedo Castro J, Ledesma-Carbayo MJ, Palacios J, Pérez-Mies B.
Tumour-infiltrating lymphocytes differ across MammaPrint® classifications in breast cancer.
ENDOCRINE-RELATED CANCER . 33(9): .
-
Lara González LE, Giudici F, Salgado R, Yan H, Rojo F, Comerma L, Wienert S, Palacios J, Kos Z, de Haas SL, Rodriguez-Lescure A, Viale G, Zheng Y, Gao D, Kiermaier A, Andre F, Loibl S, Piccart MJ, Gelber R, Cameron D, Krop IE, Savas P, Nielsen TO, Denkert C, Michiels S, Loi S.
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.
LANCET ONCOLOGY . 27(9): 1168-1180.
-
Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M.
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.
PROSTATE CANCER AND PROSTATIC DISEASES . 29(3): 588-594. Nº de citas: 10
-
Garcia-Regal C, Quiñones-Silva J, Martinez-Lorca A, Brox-Torrecilla N, Campos Mena S, Alonso-Gordoa T, Gómez-Ramírez J, Valderrabano P.
Determinants of physicians' risk-benefit perceptions of adjuvant radioactive iodine for differentiated thyroid cancer.
ENDOCRINE . 91(1): .
-
Donato S, Herrera-Martínez AD, Jacome-Gaibor VA, Ruz-Caracuel I, Toledo R, Araujo-Castro M.
Biomarkers of metastatic disease in pheochromocytoma and paraganglioma.
Endocrine Connections . 15(8): .
-
Frutos Díaz-Alejo J, Díaz de la Pinta FJ, Pavía Pascual L, Manso R, Morillo D, Moreno-Delgado M, García-Cosío M, García-Hernández S, García Fernández E, Rebollo-González M, Rodríguez M, Rodríguez Pinilla SM.
DNMT3A variants are associated with the development of nodal TFH cell lymphoma, angioimmunoblastic-type after solid tumour occurrence.
BRITISH JOURNAL OF HAEMATOLOGY . 209(2): 740-746.
-
Khan F, Polydorides AD, Paulsen JD, Vazzano J, Huber A, Papke D Jr, Sharifai N, Stashek K, Ruz-Caracuel I, Allende D, McHugh K, Shia J, Longacre TA, Dhall D, Makhoul E, Lee MJ, Collins K, Ulbright TM, Zhang ML, Westerhoff M, Gao ZH, Matsukuma K, Choi WT, Kakar S, Chetty R, Nowak K, Serra S, Zhang X, Chen W, Gonzalez RS.
Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 50(8): 883-893.
-
Grande E, Sibai M, Grases D, Andrada E, Reig O, Escobosa M, Azueta A, Castellano D, Puente J, Martínez de Villarreal J, Font A, Alonso-Gordoa T, Benítez R, Moreno-Oya A, Álvarez-Maestro M, Burgos J, Climent MA, Domínguez M, Galván P, Galante I, García JF, Perez E, García Del Muro X, Guerrero-Ramos F, Marqués M, Maroto P, Paramio JM, Pinto A, Prat A, Malats N, Durán I, Porta-Pardo E, Real FX.
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.
Cell Reports Medicine . 7(7): 102878-102878.
-
Pérez-Ruiz A, Ruiz-Cañas L, Batres S, Ferreras-Martín R, Pinto-Díez C, Yagüe B, Pérez-Morgado MI, Sacristán S, Ruz-Caracuel I, Páez SC, Sanchez-Perez I, González VM, Alcalá S, Martín ME, Sainz B Jr.
Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells.
JOURNAL OF BIOMEDICAL SCIENCE . 33(1): .
-
Riveiro-Barciela M, Esteban P, Vega-Cano KS, Mateos B, Miranda EL, Jara P, Martín M, Alonso López S, Salcedo M, Forns X, García-Fructuoso I, Martínez-Sáez O, Pinazo-Bandera J, García-Cortés M, Ribelles N, Romanos Nanclares Á, Morchón-Araujo D, Rodríguez CA, Lozano R, Domínguez-Gómez R, Cejuela M, Torres-Sempere J, Ruiz-Cobo JC, Villagrasa A, Zamora E, Buti M, Bellet M.
Clinical features and management for CDK4/6 inhibitor-DILI.
JHEP Reports . 8(7): 101873-101873.
-
Martin-Moro F, Alcoceba M, Romero S, Marquet-Palomanes J, Alonso-Castronuño D, Astibia-Mahillo B, Andreu R, Perez-Alonso R, Rodriguez-Martin E, De Ramon C, Solano I, Martin Garcia-Sancho A, Piris-Villaespesa M, Blanco O, Roldan-Santiago E, Garcia-Marco JA, Subira D, Navarro-Bailon A, Garcia-Cosio M, Garcia-Vela JA, Lopez-Jimenez J.
Phenotypic Characterization of Richter Transformation and De Novo Diffuse Large B-Cell Lymphoma With or Without Monoclonal B-Cell Lymphocytosis.
MODERN PATHOLOGY . 39(7): 101009-101009.
-
Mascaró-Baselga P, Rodellar Sanz JM, Nunes da Silva T, Hernando J, García-Álvarez A, González Merino C, Molina-Cerrillo J, Fernandez-Pombo A, Iglesias-Alvarez G, Ceballos Lenza I, Plana Serrahima M, Bella Cueto MR, Isidro ML, Martinez Trufero J, Marquina G, Martinez N, Crespo G, Jimeno R, Lorenzo I, Ayala de Miguel P, Alcazar V, Martínez-Badal S, Capdevila J, Alonso-Gordoa T.
Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.
ONCOLOGIST . 31(7): .
-
López-Robles J, Mitjavila M, Jimenez-Fonseca P, Marín-Melero I, Belló P, Pubul V, Garcia-Burillo A, Hernando J, Llana B, Ardila J, Arbizu J, Valverde R, Velasco M, Castellón M, Alonso-Gordoa T, García-Cañamaque L, Cano JM, Tabuenca MJ, Riesco MC, Custodio AB, Piñeiro A, Balaguer-Muñoz D, Nevares M, Carmona-Bayonas A.
Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?
ONCOLOGIST . 31(7): .
-
Barretina-Ginesta MP, Redondo A, Cortés-Salgado A, Madariaga A, Pérez-Mies B, Sancho L, Valls-Masot L, Domínguez M, González-Martín A.
Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(6): 104684-104684. Nº de citas: 1
-
Molina-Cerrillo J, Sierra-Ramirez A, López-Aceituno JL, Méndez-Pertuz M, Alonso-Gordoa T, Linnebacher M, Santoni M, Fernandez-Marcos PJ, Grande E.
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors.
DRUGS IN R&D . 26(2): 155-167.
-
Peg V, Burgués O, Ruiz I, Carcedo D, García JF, Monzón Naranjo MA, Tonic I, Echeverría T, Segura A, Alfonsín N, Fiaño MC, Pérez-Mies B.
A Decade of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer in Spain: A Comprehensive Real-World Data Analysis (2013-2023).
Clinical Breast Cancer . 26(6): .
-
Garrigós L, Ruiz-Borrego M, Pérez-García JM, Guerrero-Zotano A, Cortés-Salgado A, Kuemmel S, Colleoni M, Reboredo-Rendo C, Bermejo B, Blancas I, Gavila J, Fabi A, Morales C, Stradella A, Carañana V, Martínez-de Dueñas E, Albacar C, Ballesteros-Cidras O, Martrat G, Iacobucci S, Boix O, Berenguer-Molins P, Alcalá-López D, Cortés J, Llombart-Cussac A.
A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.
ANNALS OF ONCOLOGY . 37(6): 837-848.